drugset / Trial / NCT04643301
Liraglutide for Low-responders After Bariatric Surgery
NaSingle-groupOpen-labelOther
Summary
To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.
Timeline
- Start
- 2020-12-21
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 3 mg | Subcutaneous |